GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...

Ojjaara (momelotinib) is the only approved treatment for newly diagnosed and previously treated myelofibrosis patients i who ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

The California Hotel & Lodging Association (CHLA), in partnership with Oxford Economics, today released the final statewide and regional data from their Hotel Caring initiative, showing that ...

This milestone... at 13:00 Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia GSK announced today that Health Canada has approved ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.

Prithviraj Bose, MD, discusses the most critical adverse effects seen with each of the 4 approved JAK inhibitors for the treatment of myeloproliferative neoplasms.

2024 /CNW/ - GSK announced today that Health Canada has approved Ojjaara (momelotinib) for the treatment of s... Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 ...

Ojjaara, which is launched in the U.S., Europe, and very recently in Japan has seen quick adoption with high quarter-on-quarter growth. And in the U.S., it's maintaining its fast launch uptake ...